A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 2, 2013, Pages 145-150

  Lippolis, G ^a   Edsjo A ^b   Stenman, U H ^c   Bjartell, A ^a  

^a LUND UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

ERG; immunohistochemistry; radical prostatectomy; SPINK1; TATI

Indexed keywords

TRANSCRIPTION FACTOR ERG; TUMOR ASSOCIATED TRYPSIN INHIBITOR PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CELL POPULATION; COMPUTER MODEL; CONTROLLED STUDY; FUSION GENE; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY DOUBLE STAINING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE MICROARRAY; TUMOR CELL;

AGED; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TREATMENT OUTCOME; TRYPSIN INHIBITOR, KAZAL PANCREATIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84882452079     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.7     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004; 100: 2362-2366. (Pubitemid 38657883)
3. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 2011; 50(Suppl 1): 61-75.
4. Bjartell A, Montironi R, Berney DM, Egevad L. Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol 2011; 50(Suppl 1): 76-84.
5. Roobol MJ, Haese A, Bjartell A. Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol 2011; 50(Suppl 1): 85-89.
6. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007; 7: 233-245. (Pubitemid 46480968)
7. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648. (Pubitemid 41528150)
8. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20: 538-544. (Pubitemid 46631996)
9. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007; 60: 1238-1243. (Pubitemid 350084545)
10. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66: 8337-8341. (Pubitemid 44449140)
11. Fine SW, Gopalan A, Leversha MA, Al-Ahmadie HA, Tickoo SK, Zhou Q et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 2010; 23: 1325-1333.
12. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009; 69: 1400-1406.
13. Rubio-Briones J, Fernandez-Serra A, Calatrava A, Garcia-Casado Z, Rubio L, Bonillo MA et al. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol 2010; 183: 2054-2061.
14. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008; 13: 519-528. (Pubitemid 351763901)
15. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramaki OR et al. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 2010; 16: 2845-2851.
16. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 2011; 3: 72ra17.
17. Bismar TA, Yoshimoto M, Duan Q, Liu S, Sircar K, Squire JA. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology 2012; 60: 645-652.
18. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R et al. Antibodybased detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12: 590-598.
19. van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol 2011; 24: 1128-1138.
20. Fleischmann A, Schlomm T, Huland H, Kollermann J, Simon P, Mirlacher M et al. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res 2008; 14: 7838-7842.
21. Osman S, Turpeinen U, Itkonen O, Stenman UH. Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods 1993; 161: 97-106.
22. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, Hemminki A et al. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol 2007; 52: 1670-1679.
23. Falzarano SM, Zhou M, Carver P, Tsuzuki T, Simmerman K, He H et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch 2011; 459: 441-447.
24. Dahlman A, Rexhepaj E, Brennan DJ, Gallagher WM, Gaber A, Lindgren A et al. Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. Mod Pathol 2011; 24: 708-719.
25. Erbersdobler A, Isbarn H, Steiner I, Schlomm T, Chun F, Mirlacher M et al. Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. Urology 2009; 74: 1169-1173.
26. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011; 17: 5878-5888.
27. Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 13: 228-237.